Evidence map›Paper›PMID 41824789›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Hypofractionated Radiotherapy Induces ISG15

Lichao Liu, Haihong Wang, Mingjie Li, Qian Xu, Linlin Zheng, Chaoqun Han, Zhenwei Zou, Jinghua Ren, Xiaorong Dong, Peng Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lichao LiuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID https://orcid.org/0009-0001-7314-1555
Haihong WangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Mingjie LiCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qian XuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Linlin ZhengCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chaoqun HanDepartment of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhenwei ZouCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jinghua RenCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaorong DongCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Peng ZhangDepartment of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Kaixiong TaoDepartment of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhenyu LinCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Tao ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID https://orcid.org/0000-0003-4018-3393

Funding

Chinese Society of Clinical Oncology Y-2022HER2AZZD-0374Chinese Society of Clinical Oncology (CSCO)-Tongshu Oncology Research Fund Y-tongshu2021/qn-0205Huazhong University of Science and Technology Interdisciplinary Research Support Program 2025JCYJ065"Jiebang Guashuai" Project for Clinical Specialties of Wuhan Union Hospital 2025JBGS1003National Key Technology Research and Development Programme of Hubei Province SHFZ202400031National Natural Science Foundation of China 82203808National Natural Science Foundation of China 82573302Natural Science Foundation of Hubei Province of China-Hengrui Medicine Joint Fund for Innovative Development 2025AFD771Open Research Fund of Hubei Province Key Laboratory of Precision Radiation Oncology 2024ZLJZFL012Scientific Research Fund of Wuhan Union Hospital-Joint Research Fund 2023XHYN003Shenzhen Basic Research Fund JCYJ20240813153408011
6 · The paper itself

Abstract

Our previous clinical trials had demonstrated that neoadjuvant hypofractionated radiotherapy (HFRT) combined with immunotherapy yields promising clinical outcomes in locally advanced rectal cancer (LARC). However, this combined modality benefits only a subset of patients, highlighting the need to uncover the mechanisms underlying how successful immunotherapy changes the tumor microenvironment to favor tumor control. Here, we showed that HFRT increases ISG15

Indexed as

CytokinesImmune Checkpoint InhibitorsNeutrophilsRadiation Dose HypofractionationRectal NeoplasmsAnimalsFemaleHumansMiceTumor MicroenvironmentCytokinesImmune Checkpoint Inhibitorshypofractionated radiotherapyimmunotherapyISG15+MHC‐I+ neutrophilsLARCNOD1 pathway

Identifiers

PMID41824789
PMCPMC13205831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.